BIOSYSTEMS INTERNATIONAL
Executive summary:
Mission: BSI significantly improves pharmaceutical drug discovery and
development
productivity (i.e. safer and more effective drugs at lower costs and in
less time) and disease
management (i.e. drug prescription decision support for physicians) by
bringing qualified
biomarkers to the bedside.
Who we are: BSI merges pharmaceutical and diagnostics industry experience
with leading
scientific and technology expertise and know-how in separation science,
proteomics and
immunology.
What we do: BSI rapidly discovers, validates and qualifies biomarkers
through partnerships
with pharmaceutical and biotechnology companies and in house programs
The advantage of the BSI approach: BSI technology uniquely combines high
throughput
monoclonal antibodies technology and nano-volume integrated mass
spectrometry. It allows
BSI to achieve the quantitative analysis of virtually all proteins in
bodily fluids of patients and
control subjects with the sensitivity and precision of ELISA assays. BSI
builds a streamlined
strategy to identify, validate and qualify the most promising biomarkers
via a process that
includes confirmation of clinical relevance on large patient cohorts of
phase II and phase III
clinical trials.
BSI partner benefits:
1) expertise and know-how in the form of data, information and knowledge
respective to the
process of identifying, validating and qualifying biomarkers
2) tools (e.g. monoclonal Antibodies) to enable partners to detect
biomarker presence
and/or activity in patients involved in clinical trials
What type of partnership is BSI looking for?
BSI is primarily looking for partnerships whose terms of retribution would
combine cash
components and intellectual property (IP) sharing.
Senior management team
- President and chief scientific officer: Laszlo Takacs (from Pfizer)
- Chief operating officer: Andrea Hollai
- Chief technology officer: Andras Guttman (from Diversa and University of
Innsbruck)
Business strategy
The company aims to create value out of:
1. Know how and expertise in Biomarker Discovery, Validation and
Qualification
Services
2. Tools for Biomarker Discovery (such as monoclonal antibodies)
3. Products such as Biomarker Detection and Monitoring Tool Kits for
clinical trials,
clinical diagnostics and disease management.
